abrdn plc Invests $1.17 Million in TScan Therapeutics, Inc. (NASDAQ:TCRX)

abrdn plc acquired a new stake in TScan Therapeutics, Inc. (NASDAQ:TCRX) during the 4th quarter, Holdings Channel.com reports. The firm acquired 200,000 shares of the company’s stock, valued at approximately $1,166,000.

Separately, Pale Fire Capital SE bought a new stake in shares of TScan Therapeutics during the 3rd quarter valued at $42,000. 82.83% of the stock is owned by institutional investors.

Analysts Set New Price Targets

TCRX has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a research report on Thursday, March 7th. Wedbush restated an “outperform” rating and issued a $10.00 price target on shares of TScan Therapeutics in a report on Tuesday, April 23rd.

TScan Therapeutics Trading Up 4.9 %

TScan Therapeutics stock opened at $7.68 on Tuesday. TScan Therapeutics, Inc. has a one year low of $1.62 and a one year high of $9.00. The company has a market cap of $367.72 million, a price-to-earnings ratio of -4.06 and a beta of 0.90. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.51 and a quick ratio of 6.51. The firm has a 50-day moving average of $7.20 and a 200-day moving average of $5.88.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings results on Wednesday, March 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.08. The firm had revenue of $7.21 million for the quarter, compared to analyst estimates of $2.94 million. TScan Therapeutics had a negative net margin of 423.86% and a negative return on equity of 60.65%. On average, equities analysts expect that TScan Therapeutics, Inc. will post -1.03 earnings per share for the current fiscal year.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.